Summary Verona Pharma (VRNA) shows strong technical indicators with a 54.89% gain since 11/19, driven by Barchart's Trend Seeker buy signal. The company focuses on developing ensifentrine for respiratory...
DAVID ZACCARDELLI, the President and CEO of $VRNA ($VRNA), sold 162,800 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.1%...
Mark W Hahn, the Chief Financial Officer of $VRNA ($VRNA), sold 12,936 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1%...
For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...
It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...
A strong pipeline of products could potentially transform these companies, but there are risks.
The healthcare sector is no slouch when it comes to top-performing growth stocks.
Don't be surprised if these three stocks take off in the new year.
Investors hoped for a rebound in the stock market, but they might have to settle for gains in these two stocks.
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.